Gilead Sciences Current Debt increased by 0.0% to $2.81B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 54.7%, from $1.82B to $2.81B. Over 5 years (FY 2020 to FY 2025), Current Debt shows relatively stable performance with a 0.4% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase signals a looming requirement for cash or a need to refinance existing debt in the near term.
The segment of a company's total long-term debt obligations that is scheduled for repayment within the upcoming fiscal y...
This metric is compared against current assets to determine if the company can meet its immediate debt obligations without external financing.
current_portion_long_term_debt| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.26B | $2.51B | $1.52B | $1.03B | $1.02B | $2.27B | $2.27B | $2.28B | $4.04B | $1.79B | $1.80B | $3.67B | $1.81B | $1.81B | $1.82B | $2.81B | $2.81B | $2.81B | $2.81B |
| QoQ Change | — | +11.1% | -39.6% | -32.4% | -0.4% | +122.3% | +0.1% | +0.4% | +76.8% | -55.6% | +0.3% | +103.9% | -50.7% | +0.2% | +0.2% | +54.6% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | — | -54.8% | -9.6% | +49.9% | +122.7% | +295.4% | -21.0% | -20.9% | +60.6% | -55.2% | +1.1% | +0.9% | -23.5% | +55.1% | +54.9% | +54.7% |
We use cookies for analytics. See our Privacy and Cookie Policy.